➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Harvard Business School
Colorcon
Dow
Moodys

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

DATSCAN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Datscan patents expire, and what generic alternatives are available?

Datscan is a drug marketed by Ge Hlthcare Inc and is included in one NDA.

The generic ingredient in DATSCAN is ioflupane i-123. One supplier is listed for this compound. Additional details are available on the ioflupane i-123 profile page.

Summary for DATSCAN
Drug patent expirations by year for DATSCAN
Recent Clinical Trials for DATSCAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cedars-Sinai Medical CenterPhase 2
PPDPhase 3
GE HealthcarePhase 3

See all DATSCAN clinical trials

Pharmacology for DATSCAN

US Patents and Regulatory Information for DATSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Hlthcare Inc DATSCAN ioflupane i-123 SOLUTION;INTRAVENOUS 022454-001 Jan 14, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DATSCAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0703791 03C0021 France   Start Trial PRODUCT NAME: IOFLUPANE (123 I); REGISTRATION NO/DATE: EU/1/00/135/001 20000727
0703791 SPC/GB03/010 United Kingdom   Start Trial PRODUCT NAME: IOFLUPANE (123I) OR (123I)-2-BETA-CARBOMETHOXY-3-BETA-(4-IODOPHENYL)-8-(3-FLUOROPROPYL)-NORTROPANE; REGISTERED: UK EU/1/00/135/001 20000802
0703791 CA 2003 00010 Denmark   Start Trial
0703791 9/2003 Austria   Start Trial PRODUCT NAME: IOFLUPANE (123I); REGISTRATION NO/DATE: EU/1/00/135/001 20000727
0703791 300123 Netherlands   Start Trial
0703791 C300123 Netherlands   Start Trial PRODUCT NAME: IOFLUPANE (123I); NAT. REGISTRATION NO/DATE: EU/1/00/135/001 20000727; FIRST REGISTRATION: EU/1/00/135/001 20000727
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKesson
Baxter
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.